Cravath represented Mylan Inc. in connection with its €500 million Reg. S senior notes offering. Mylan Inc. is a wholly owned subsidiary of Mylan N.V., a leading global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The transaction closed on May 23, 2018.
The Cravath team included partner Johnny G. Skumpija and associates Alex M. Dzioba, Justin B. Stein and Jeffrey M. Amico on securities matters, and associate Kiran Sheffrin on tax matters.